VolitionRX Limited (VNRX): Price and Financial Metrics


VolitionRX Limited (VNRX): $2.31

0.08 (+3.59%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

VNRX POWR Grades

  • VNRX scores best on the Sentiment dimension, with a Sentiment rank ahead of 84.66% of US stocks.
  • The strongest trend for VNRX is in Stability, which has been heading down over the past 46 days.
  • VNRX ranks lowest in Value; there it ranks in the 8th percentile.

VNRX Stock Summary

  • The capital turnover (annual revenue relative to shareholder's equity) for VNRX is 0.04 -- better than just 10.49% of US stocks.
  • With a price/sales ratio of 520.65, VOLITIONRX LTD has a higher such ratio than 99.26% of stocks in our set.
  • Revenue growth over the past 12 months for VOLITIONRX LTD comes in at 233.9%, a number that bests 96.23% of the US stocks we're tracking.
  • If you're looking for stocks that are quantitatively similar to VOLITIONRX LTD, a group of peers worth examining would be CHPT, VLD, WATT, PROF, and QUIK.
  • Visit VNRX's SEC page to see the company's official filings. To visit the company's web site, go to www.volition.com.

VNRX Valuation Summary

  • VNRX's price/earnings ratio is -3.7; this is 116.55% lower than that of the median Healthcare stock.
  • VNRX's EV/EBIT ratio has moved up 1881.3 over the prior 130 months.

Below are key valuation metrics over time for VNRX.

Stock Date P/S P/B P/E EV/EBIT
VNRX 2022-11-01 582.0 25.3 -3.7 -3.3
VNRX 2022-10-31 587.6 25.5 -3.7 -3.3
VNRX 2022-10-28 578.9 25.1 -3.7 -3.3
VNRX 2022-10-27 561.3 24.4 -3.6 -3.2
VNRX 2022-10-26 561.3 24.4 -3.6 -3.2
VNRX 2022-10-25 558.2 24.2 -3.6 -3.2

VNRX Growth Metrics

    The 3 year net cashflow from operations growth rate now stands at 21.36%.
  • Its 5 year net cashflow from operations growth rate is now at -53.36%.
  • Its 2 year net cashflow from operations growth rate is now at 15.76%.
VNRX's revenue has moved up $176,590 over the prior 30 months.

The table below shows VNRX's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-06-30 0.193686 -12.56319 -30.4553
2022-03-31 0.178716 -11.69893 -28.33255
2021-12-31 0.090035 -20.85392 -26.81467
2021-09-30 0.082915 -19.17901 -23.91666
2021-06-30 0.058007 -18.80059 -21.10812
2021-03-31 0.038419 -17.83049 -20.61849

VNRX's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • VNRX has a Quality Grade of D, ranking ahead of 5.68% of graded US stocks.
  • VNRX's asset turnover comes in at 0.002 -- ranking 424th of 680 Pharmaceutical Products stocks.
  • CDTX, KALA, and NVS are the stocks whose asset turnover ratios are most correlated with VNRX.

The table below shows VNRX's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.002 1 -4.279
2021-03-31 0.001 1 -4.727
2020-12-31 0.001 1 -5.183
2020-09-30 0.000 1 -4.958
2020-06-30 0.001 1 -5.040
2020-03-31 0.001 1 -4.625

VNRX Stock Price Chart Interactive Chart >

Price chart for VNRX

VNRX Price/Volume Stats

Current price $2.31 52-week high $3.64
Prev. close $2.23 52-week low $1.31
Day low $2.21 Volume 190,900
Day high $2.38 Avg. volume 96,018
50-day MA $1.72 Dividend yield N/A
200-day MA $2.22 Market Cap 132.36M

VolitionRX Limited (VNRX) Company Bio


VolitionRX Limited, a clinical-stage life sciences company, focuses on developing blood-based diagnostic tests for detecting and diagnosing cancer and other diseases. The company is based in Singapore.


VNRX Latest News Stream


Event/Time News Detail
Loading, please wait...

VNRX Latest Social Stream


Loading social stream, please wait...

View Full VNRX Social Stream

Latest VNRX News From Around the Web

Below are the latest news stories about VOLITIONRX LTD that investors may wish to consider to help them evaluate VNRX as an investment opportunity.

Maxim Group Remains a Buy on VolitionRX (VNRX)

Maxim Group analyst Jason McCarthy maintained a Buy rating on VolitionRX (VNRX - Research Report) yesterday and set a price target of $5.00. The company's shares opened today at $1.98.According to TipRanks, McCarthy is an analyst with an average return of -37.8% and a 14.69% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as Immutep, Daré Bioscience, and SELLAS Life Sciences Group.Currently, the analyst consensus on VolitionRX is a Moderate Buy with an average price target of $5.00.See today’s best-performing stocks on TipRanks >>Based on VolitionRX's latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $32.

Ryan Adist on TipRanks | November 22, 2022

VolitionRx Limited Announces Third Quarter 2022 Financial Results and Business Update

VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced financial results and a business update for the third quarter ended September 30, 2022. Volition management will host a conference call tomorrow, November 15 at 8:30 a.m. U.S. Eastern Time to discuss these results. Conference call details can be found below.

Yahoo | November 14, 2022

Volition Announces Clinical Research Study with Oncovet

VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, has announced a clinical research study with Oncovet, a renowned veterinary referral clinic, specializing in medical and radiation oncology.

Yahoo | November 14, 2022

Volition to Participate in a Lung Cancer Screening Study in France

VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, has been invited to participate in a government-backed prospective study to evaluate the performance of blood biomarkers in the early detection of lung cancer with Hospices Civils de Lyon ("HCL"), France's second largest university hospital.

Yahoo | November 10, 2022

Volition Announces the Launch of the Nu.Q® Vet Cancer Screening Test in the U.S. and Europe Through Heska's Reference Laboratories

VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announces the launch of its Nu.Q® Vet Cancer Screening Test across the U.S. and the forthcoming launch in Europe by Heska Corporation (NASDAQ: HSKA) ("Heska"), a leading global provider of advanced veterinary diagnostics, through Heska's veterinary diagnostic laboratories.

Yahoo | November 3, 2022

Read More 'VNRX' Stories Here

VNRX Price Returns

1-mo 21.58%
3-mo 36.69%
6-mo N/A
1-year -33.62%
3-year -56.74%
5-year -27.81%
YTD -26.43%
2021 -19.28%
2020 -17.93%
2019 161.88%
2018 -38.44%
2017 -35.67%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7783 seconds.